Monetary Management Group’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.83M Buy
35,105
+875
+3% +$188K 1.81% 10
2026
Q1
$7.44M Hold
34,230
1.78% 11
2025
Q4
$7.82M Sell
34,230
-1,135
-3% -$259K 1.81% 9
2025
Q3
$8.19M Sell
35,365
-1,000
-3% -$204K 1.88% 10
2025
Q2
$6.75M Sell
36,365
-50
-0.1% -$9.29K 1.66% 11
2025
Q1
$7.63M Sell
36,415
-200
-0.5% -$38.9K 2.06% 10
2024
Q4
$6.51M Buy
36,615
+100
+0.3% +$18.4K 1.69% 10
2024
Q3
$7.21M Sell
36,515
-1,150
-3% -$215K 1.85% 10
2024
Q2
$6.46M Buy
37,665
+384
+1% +$63.6K 1.71% 10
2024
Q1
$6.79M Sell
37,281
-434
-1% -$74.8K 1.89% 10
2023
Q4
$5.84M Buy
37,715
+260
+0.7% +$37.9K 1.82% 9
2023
Q3
$5.58M Sell
37,455
-6,850
-15% -$1.01M 1.86% 9
2023
Q2
$5.97M Sell
44,305
-5,725
-11% -$840K 1.83% 9
2023
Q1
$7.97M Buy
50,030
+675
+1% +$103K 2.35% 5
2022
Q4
$7.98M Sell
49,355
-1,375
-3% -$211K 2.49% 5
2022
Q3
$6.81M Sell
50,730
-350
-0.7% -$50.2K 2.24% 7
2022
Q2
$7.82M Sell
51,080
-500
-1% -$76.4K 2.45% 6
2022
Q1
$8.36M Sell
51,580
-500
-1% -$72.6K 2.21% 6
2021
Q4
$7.05M Buy
52,080
+2,800
+6% +$331K 1.74% 9
2021
Q3
$5.32M Buy
49,280
+5,450
+12% +$623K 1.46% 10
2021
Q2
$4.94M Sell
43,830
-50
-0.1% -$5.63K 1.49% 10
2021
Q1
$4.75M Sell
43,880
-1,825
-4% -$195K 1.49% 10
2020
Q4
$4.9M Sell
45,705
-150
-0.3% -$14.4K 1.61% 11
2020
Q3
$4.02M Sell
45,855
-1,375
-3% -$129K 1.43% 13
2020
Q2
$4.64M Sell
47,230
-270
-0.6% -$23.8K 1.75% 9
2020
Q1
$3.62M Buy
47,500
+4,800
+11% +$409K 1.6% 12
2019
Q4
$3.78M Sell
42,700
-1,885
-4% -$156K 1.38% 14
2019
Q3
$3.38M Buy
44,585
+8,170
+22% +$560K 1.28% 19
2019
Q2
$2.65M Buy
36,415
+575
+2% +$45.2K 1.02% 26
2019
Q1
$2.89M Hold
35,840
1.14% 24
2018
Q4
$3.3M Sell
35,840
-125
-0.3% -$11K 1.49% 14
2018
Q3
$3.4M Sell
35,965
-5,810
-14% -$551K 1.3% 19
2018
Q2
$3.87M Sell
41,775
-350
-0.8% -$34.2K 1.58% 18
2018
Q1
$3.99M Sell
42,125
-375
-0.9% -$41.2K 1.65% 17
2017
Q4
$4.11M Sell
42,500
-200
-0.5% -$18.8K 1.66% 16
2017
Q3
$3.79M Sell
42,700
-3,200
-7% -$244K 1.6% 14
2017
Q2
$3.33M Sell
45,900
-50
-0.1% -$3.36K 1.36% 25
2017
Q1
$2.99M Buy
45,950
+425
+0.9% +$26.7K 1.3% 25
2016
Q4
$2.85M Buy
45,525
+75
+0.2% +$4.58K 1.32% 24
2016
Q3
$2.87M Sell
45,450
-575
-1% -$37.2K 1.33% 25
2016
Q2
$2.85M Buy
46,025
+177
+0.4% +$10.8K 1.33% 22
2016
Q1
$2.62M Hold
45,848
1.27% 23
2015
Q4
$2.72M Buy
45,848
+200
+0.4% +$11.5K 1.3% 25
2015
Q3
$2.48M Sell
45,648
-2,000
-4% -$130K 1.24% 25
2015
Q2
$3.2M Buy
47,648
+1,675
+4% +$109K 1.44% 16
2015
Q1
$2.69M Buy
45,973
+9,200
+25% +$556K 1.19% 22
2014
Q4
$2.41M Buy
36,773
+9,025
+33% +$569K 1.07% 29
2014
Q3
$1.6M Buy
27,748
+3,600
+15% +$200K 0.74% 43
2014
Q2
$1.36M Buy
24,148
+4,900
+25% +$257K 0.64% 54
2014
Q1
$989K Sell
19,248
-19,875
-51% -$1M 0.46% 68
2013
Q4
$2.07M Buy
39,123
+250
+0.6% +$12.3K 0.96% 38
2013
Q3
$1.74M Hold
38,873
0.91% 44
2013
Q2
$1.61M Buy
+38,873
New +$1.7M 0.88% 38

Other funds holding ABBV

Monetary Management Group's ABBV Position: Q2 2026 in Review

Monetary Management Group increased its AbbVie (ABBV) stake by 2.6% in Q2 2026, buying an estimated $188K and bringing the position to 35,105 shares worth $8.83M. The position accounts for 1.81% of the portfolio, ranked #10.

Monetary Management Group first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Monetary Management Group held 35,105 shares of AbbVie worth $8.83M as of Q2 2026.
  • Monetary Management Group bought 875 AbbVie shares in Q2 2026, an estimated $188K.
  • AbbVie made up 1.81% of Monetary Management Group's portfolio in Q2 2026, its #10 holding.
  • Monetary Management Group first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Monetary Management Group's 13F filing for Q2 2026, filed 12 Aug 2026.